Benchmarks for prescribing and assessing the effectiveness of psychopharmacotherapy: discordance between subjective and observed assessment of depression in adolescents with affective disorders and schizophrenia-spectrum disorders
Psychopharmacology and Addiction Biology · 14.09.2026 · 17 (2) · 81-94
DOI: 10.17816/phbn713981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology and Addiction Biology, online erschienen am 14.09.2026. Verfasst von Khadizhat G. Ibragimova und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Data on the concordance between clinician-rated and self-rated depression in adolescents with various mental disorders are extremely limited, which complicates the interpretation of psychopharmacological studies and the determination of treatment efficacy. Most studies in this area have focused on mean values, whereas the variability of discordance, particularly in schizophrenia-spectrum disorders, remains unexplored. AIM: To identify the patterns of discordance between subjective and observed assessment of depression in adolescents with affective disorders and schizophrenia-spectrum disorders in order to improve the accuracy of psychometric measurements in psychopharmacological studies and clinical practice. METHODS: A cross-sectional comparative study included 60 hospitalized adolescents aged 13–17 years: 30 with affective disorders (group F3) and 30 with schizophrenia-spectrum disorders (group F2). In both groups, the Zung Self-Rating Depression Scale (SDS) was used for self-assessment and the Montgomery–Åsberg Depression Rating Scale (MADRS) for clinician rating; in group F2, the Calgary Depression Scale for Schizophrenia (CDSS) was additionally administered. Scores were normalized to the maximum score and expressed as percentages (0%–100%). The bias index (BI) was calculated as the difference between normalized MADRS and SDS scores. The statistical analysis included nonparametric methods. The primary endpoint was the difference in BI variance (Levene test); secondary endpoints included between-group differences in BI and in normalized SDS and MADRS scores (Mann–Whitney U test) and rank correlations (Rs) between these scores (Fisher Z transformation). A sensitivity analysis with scale substitution was performed (Steiger test). RESULTS: The variance of the BI was substantially higher in group F2 than in group F3 (592.44 vs 50.98; F = 23.95; p 0.001). The median BI values (−3.33 in group F3 and −5.00 in group F2) did not differ (p = 0.749). Normalized SDS scores in group F3 were higher than in group F2 (55.00 vs 41.67; p 0.001), whereas normalized MADRS scores did not differ (50.83 vs 41.67; p = 0.496). The correlation between SDS and MADRS in group F3 was strong (Rs = 0.728; p 0.001) and weak in group F2 (Rs = 0.151; p = 0.425; Z = 2.84; p = 0.005). Replacing the MADRS scale with the CDSS in group F2 improved concordance (Rs = 0.372; p = 0.035), while between-group differences persisted (Z = 1.97; p = 0.049). CONCLUSION: The discordance between self-rated and clinician-rated depression in adolescents with schizophrenia-spectrum disorders is characterized by high variability and low coherence, in contrast to the relatively homogeneous and predictable pattern in adolescents with affective disorders. This difference may be related to impaired insight and cognitive deficits. The results of the study indicate the unreliability of using self-report as a benchmark for prescribing and assessing the efficacy of psychopharmacotherapy. Thus, in psychopharmacological studies and routine practice, subjective self-report requires mandatory cross-verification using clinical scales.
Zitieren
APA
Ibragimova, K. G., & Popov, M. Y. (2026). Benchmarks for prescribing and assessing the effectiveness of psychopharmacotherapy: discordance between subjective and observed assessment of depression in adolescents with affective disorders and schizophrenia-spectrum disorders. Psychopharmacology and Addiction Biology, 17(2), 81-94. https://doi.org/10.17816/phbn713981
Vancouver
Ibragimova KG, Popov MY. Benchmarks for prescribing and assessing the effectiveness of psychopharmacotherapy: discordance between subjective and observed assessment of depression in adolescents with affective disorders and schizophrenia-spectrum disorders. Psychopharmacology and Addiction Biology. 2026;17(2):81-94. doi:10.17816/phbn713981
BibTeX
@article{Ibragimova2026,
author = {Ibragimova, Khadizhat G. and Popov, Mikhail Yu.},
title = {Benchmarks for prescribing and assessing the effectiveness of psychopharmacotherapy: discordance between subjective and observed assessment of depression in adolescents with affective disorders and schizophrenia-spectrum disorders},
journal = {Psychopharmacology and Addiction Biology},
year = {2026},
volume = {17},
number = {2},
pages = {81--94},
doi = {10.17816/phbn713981}
}
EUVIMED